On the other hand, with a pre-therapeutic median irinotecan dose reduction equal to 40%, we observed among 27 UGT1A1*28 homozygous carriers a 39% rate of grade ≥ 3 neutropenia. This evidence concerns the gene UGT1A1 and neutropenia.